{ "ticker": "SNOA", "company": "Sonoma Pharmaceuticals, Inc.", "cik": "0001367083", "exchange": null, "gics_sector": "Health Care", "industry": "Health Care", "logo_url": "https://www.google.com/s2/favicons?domain=sonomapharma.com&sz=128", "from_state": "DE", "to_state": "NV", "effective_date_iso": null, "actual_effective_date_iso": null, "proposed_effective_date_iso": null, "source_confidence": "COMPANY_RELEASE", "is_legal_precedent": 0, "vote_mechanism": null, "approval_basis": "For \u00f7 outstanding voting power (DGCL \u00a7266 conversion)", "threshold_result": null, "event_type": null, "two_attempt_flag": 0, "prior_failed_vote_flag": 1, "governance_concession_redo_flag": 0, "subsequent_event_flag": 0, "subsequent_event_type": null, "subsequent_event_date_iso": null, "subsequent_event_note": null, "public_tier": "VERIFIED_TRACKER", "event_study_announcement_json": "{\"event_date\":\"2026-04-24\",\"event_kind\":\"announcement\",\"event_tag\":\"announcement\",\"t0_source_field\":\"announcement_date_iso\",\"estimation_window\":\"trailing 240 days; 240 valid after NaN drop\",\"specifications\":[{\"name\":\"Market model (SPY benchmark)\",\"day0_ar\":-0.37256112169010097,\"p_value\":1.9800041606288232e-09,\"p_label\":\"Patell-z p-value\",\"extra\":{\"alpha\":-0.001863603944636458,\"beta\":1.001131694562498,\"r2\":0.01614189819068179,\"sigma\":0.06187732071076205},\"is_headline\":true}],\"_meta\":{\"n_valid_pre_days\":240},\"_source\":\"Source B: phase4v3 NaN-safe runner (1 spec, 2026-04-29 yfinance pull); Source A unavailable for this firm; joined by phase5z_join_full_battery.py\"}", "announcement_date_iso": "2026-04-27", "meeting_date_iso": "2026-06-24", "vote_result": "SCHEDULED", "status_label": "SCHEDULED", "market_cap_usdmm": 6.2, "bucket_class": "D", "public_bucket_code": "D", "public_bucket_label": "Pending / scheduled / rejected", "public_bucket_subcode": null, "panel_eligibility": "PANEL_A_post_SB29", "transaction_status": "PENDING", "audit_status": "VERIFIED_PROXY", "audit_notes": "Phase 3M 2026-04-27: status=SCHEDULED \u2014 moved None from actual to proposed_effective_date_iso. Will promote to actual after vote passes. | [2026-04-28] Phase 4E ad-hoc filing ingest: PRE 14A 0001683168-26-003211 (filed 2026-04-27). Updates: announcement_date_iso, edgar_accession_canonical, audit_status, status_label_dashboard, vote_result. | Phase 4F: PRE 14A verified \u2014 SECOND reincorporation attempt for DE\u2192NV. Prior vote 2024-08-22 FAILED: For 2,790,999 / Against 490,070 / Abstain 33,663 (85.1% of votes cast in favor, but proposal required majority of outstanding shares \u2014 turnout too low to meet the threshold). Filing 0001683168-26-003211 on 2026-04-24 schedules a special meeting for 2026-06-24. Approval standard remains majority of outstanding shares; abstentions and broker non-votes effectively count against. Stated rationale: eliminate ~$200K/yr Delaware franchise tax. Research significance: rare within-firm repeated-measures case (same firm, same proposal, same approval threshold, two attempts) \u2014 flag for Panel A robustness. | [2026-04-28] Phase 4I: replaced Google-search IR fallback with direct URL https://investors.sonomapharma.com/\n[2026-04-29] phase5u: row independently validated by external Reviewer (full-residual pass, 78/276 substantive answers); validations applied: V_DATE_ANN=CONFIRM; V_DATE_MEET=CONFIRM; V_DATE_EFF=NOT_YET_EFFECTIVE; V_FROM_TO=CONFIRM; V_BUCKET=CONFIRM; V_COHORT=CONFIRM_INCLUSION; primary-source URLs all under https://www.sec.gov/Archives/\n[2026-04-29] phase5v: row independently re-validated by external Reviewer (Round 4 full-residual pass, 85/276 substantive); all bucket and pending-status conclusions match v3.57\n[2026-04-29] phase5w: comprehensive validation by external reviewer across tranches v6 (4-version full residual walk, 269 substantive answers across 52 firms, 0 bucket drifts vs v3.58)\n[2026-04-29] phase5x: SNOA prior_failed_vote_flag set to 1; prior_vote_date_iso = 2024-08-22 (first reincorporation vote attempt failed DE outstanding-shares threshold; second attempt scheduled 2026-06-24 per PRE 14A acc 0001683168-26-003211); rare within-firm repeated-measures case for Panel A robustness; Decision #3 per Shane 2026-04-29 | [2026-04-29] v3.75: VERIFIED MECHANISM \u2014 TWO-ATTEMPT firm. (1) 2024 attempt: REJECTED via DGCL \u00a7266 conversion. (2) Current scheduled second attempt. Standard: DGCL \u00a7266 majority-of-outstanding-voting-power. Cited rationale: $200K/yr Delaware franchise tax \u2192 <$1K/yr Nevada; broader D&O liability exclusion under NRS 78.138. | [2026-04-29] v3.84-rev1 EVENT-DATE CORRECTION (reviewer 2 / Anthropic concern #1): announcement_date_iso changed from 2026-04-24 to 2026-04-27. April 24 was the day Sonoma announced a $4M dilutive equity offering (2,962,963 shares @ $1.35; Form S-1 declared effective by SEC 2026-04-23; underwriter Dawson James) \u2014 a same-day idiosyncratic shock unrelated to corporate domicile. The reincorporation PRE 14A acc 0001683168-26-003211 was filed 2026-04-27 per Phase 4E audit and confirmed by post-event volume normalization. Capital IQ (Interactive Data Pricing) confirms split-adjusted prices: April 23 close $1.80, April 24 close $1.14 (-36.67% raw, real economic event but driven by dilution), April 27 close $1.11 (-2.63% raw, normal volume 427K). Provisional Day-0 AR = -2.63% (raw return); full market-model recompute pending next yfinance sync. | v3.84-rev5c [2026-04-30] promoted to HIGH date_quality_flag per v3.84-rev1 EDGAR-verified primary-source date correction (event-date fix from financing day to reincorporation announcement); primary-source EDGAR confirmation.", "edgar_accession": "0001683168-26-003211", "edgar_accession_note": null, "links": [ { "label": "IR", "url": "https://investors.sonomapharma.com/", "link_type": "ir" }, { "label": "EDGAR", "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367083&type=&dateb=&owner=include&count=40", "link_type": "search" }, { "label": "Proxy", "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367083&type=DEF+14A&dateb=&owner=include&count=40", "link_type": "search" } ], "car": { "value": -0.439612, "significant_5pct": 0, "specification": "BHAR_3mo_FFC6", "event_date": "2024-08-15", "source": "05_REVIEWER_AUDIT_PACKAGE/data/bhar_per_firm_v1.2.3.csv", "status": "ESTIMATED", "bhar_3mo": -0.439612, "bhar_6mo": -0.522199 }, "votes_for": null, "votes_against": null, "votes_abstain": null, "votes_broker_nonvote": null, "approval_pct": null, "votes_for_disinterested": null, "votes_against_disinterested": null, "votes_abstain_disinterested": null, "votes_broker_nonvote_disinterested": null, "approval_pct_disinterested": null, "approval_basis_disinterested": null, "announcement_PRE_14A_accession": null, "announcement_PRE_14A_url": null, "vote_source_8k_accession": null, "vote_source_8k_url": null, "vote_proposal_title": null, "meeting_type": null, "approval_standard": "majority of the voting power of the outstanding stock entitled to vote (DGCL \u00a7266 conversion)", "companion_proposal": null, "proxy_advisors": null, "management_response": null, "press_coverage": [], "prior_vote": { "attempt_count": null, "date_iso": "2024-08-22", "votes_for": null, "votes_against": null, "votes_abstain": null, "outcome": null, "approval_pct_of_cast": null }, "panel_a_tx_incumbent": 0, "panel_b_dexit_mover": 1, "texas_statutory_adoptions": { "tboc_21_552": { "name": "SB 29 \u2014 TBOC \u00a721.552 derivative threshold", "adopted": 0, "source": null, "url": null, "date": null }, "tboc_21_373": { "name": "SB 1057 \u2014 TBOC \u00a721.373 shareholder-proposal threshold", "adopted": null, "source": null, "url": null, "date": null } }, "announcement_source_type": "PRE14A", "announcement_accession_verified": "Y", "date_quality_flag": "HIGH", "controlled": null, "controller_pct_voting_power": null, "controller": null, "controller_source": "UNKNOWN", "_evidence_strength": { "badge": "BRONZE", "score": 35, "max": 100, "components": { "source_confidence": 10, "vote_totals": 0, "effective_date": 0, "car_estimate": 10, "edgar_accession": 15 } }, "_context_callout": "Vote scheduled for 2026-06-24; results pending.", "_generated_at": "2026-04-30" }